Nov 4, 2020|
JD Becomes China’s First Online Platform Offering Eli Lilly’s New Drug for Diabetes
by Hui Zhang
Eli Lilly and Company, a global leading pharmaceutical company, expanded its cooperation with JD Health by offering its innovative hypoglycemic drug Trulicity® (dulaglutide) to diabetes patients through the platform. JD Health is the first online platform in China selling the drug.
Both sides also agreed to further deepen cooperation in areas such as setting up a specialized disease center, building an online education channel which will offer health-related knowledge, online consultation, and product sales.
The prevalence of diabetes in China has been on the rise, and most diabetic patients need to take long-term or even lifelong medication. Therefore, improving the accessibility of diabetes medication is crucial.
A number of global pharmaceutical companies, such as Novartis, AstraZeneca and Eisai, have chosen JD Health as the first or exclusive platform in China to offer their innovative drugs. Leveraging JD’s omnichannel solution by working with offline pharmacies to improve delivery efficiency and its cold-chain delivery service, JD Health is committed to empowering people in health management.